VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

Institution: IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) SOHO Italy 2022 | Exciting advances in DLBCL: molecular characterization of subtypes & novel immunotherapeutic agents

Gerardo Musuraca, MD, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), Meldola, Italy, highlights exciting advances in diffuse large B-cell lymphoma (DLBCL), including the importance of molecular characterization of various subtypes of DLBCL, and the promise of novel immunotherapies, including CAR-T therapy and bispecific antibodies. This interview took place at The 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter